MAMMOLOGY. TOPICAL ISSUE
MAMMOLOGY. DIAGNOSIS
The use of digital techniques in mammography has become a last step for completing the process of digitization in diagnostic imaging. It is assumed that such a spatial decision will be required for digital mammography, as well as for high-resolution intensifying screen-film systems used in conventional mammography and that the digital techniques will be limited by the digitizer pixel size on detecting minor structures, such as microcalcifications. The introduction of digital technologies in mammography involves a tight control over an image and assures its high quality.
Preoperative verification of breast cancer (BC) is a necessary stage of diagnosis. The main method for obtaining materials is fine-needle aspiration biopsy that is of low informative value in a number of cases. Histological biopsy of nonpalpable breast masses extends the verification capabilities of accurate diagnosis and determines the choice and tactics of combination and complex treatments in patients with BC just at a preoperative stage, and, in case of detection of a benign tumor, enables one to abandon sector resection with an urgent histological study.
MAMMOLOGY. TREATMENT
The paper considers the current feasibility of endocrine therapy for breast cancer (BC). It presents trials of the efficacy of fulvestrant in the treatment of patients with BC. Practically all clinical trials have demonstrated that the drug is well tolerated, without causing any significant systemic estrogen-like effects, as well as complications associated with the use of aromatase inhibitors.
Objective: to evaluate the efficiency (morphological tumor complete regression (mCR), a clinical effect) and safety of the use of new anthracycline-free neoajuvant chemotherapy regimens (paclitaxel + vinorelbine and docetaxel + carboplatin) in combination with trastuzumab in patients with Stage IIIa-c breast cancer (BC) and Her-2 hyperexpression.
Subjects and methods. The study enrolled 36 Stage IIIa–c BC patients receiving 4–8 cycles of a chemotherapy regimen of paclitaxel (100 mg/m2) + vinorelbine (25 mg/m2) (every 3 weeks) or docetaxel (50 mg/m2) + carboplatin (AUC 5) (every 3 weeks) in combination with trastuzumab.
Results. The docetaxel (75 mg/m2) + carboplatin (AUC 5) + trastuzumab regimen demonstrated a high effectiveness with acceptable toxicity. Seventeen (58.8 %) patients achieved mCP. The clinical effect was 83.3 % (4 complete and 11 partial tumor regressions).
The paclitaxel (135 mg/m2) + vinorelbine (25 mg/m2) (every 3 weeks) + trastuzumab regimen is efficacious and promising when the doses of the drugs are increased and granulocyte colony-stimulating factor used.
MAMMOLOGY. PROBLEM
The results of social inquiry of 400 patients with breast cancer being on treatment in Belgorod Oncological Dispensary are shown. It is noted that 50–60 % of this women can not inquire themselves with psychological burden, they are in need of help of psychologists on all stages of treatment and observation. In connection with particular medical and social meaning of this problem the elaboration of effective programs of the psychological rehabilitation and social adaptation will be necessary.
GYNECOLOGY. DIAGNOSIS
Objective: to study the pathomorphological signs of pure and mixed clear-cell ovarian tumors with a clear-cell component.
Subjects and methods. The clinical and morphological characteristics and the course of the disease were analyzed in 96 patients aged 21 to 75 years with clear-cell ovarian carcinoma. All the patients were divided into 2 groups: 1) 71 patients with pure clear-cell ovarian adenocarcinomas (COA) and 2) 25 patients with mixed malignant ovarian epithelial tumors (MMOET) with an obligatory clear-cell component. All pure forms of ovarian clear-cell malignancies were represented by adenocarcinoma in our study. This histologic type of the tumor was also prevalent among mixed ovarian neoplasms.
Results. Clear, optically transparent cells and shoe nail-type (nail) ones were most common in COA. MMOETs showed moderate dif- ferentiation and malignancy and moderate atypia of a cell. Pure clear-cell neoplasms generally displayed 3 to 6 mitoses in 10 fields of vision whereas MMOET exhibited as many as 3 mitoses in 10 fields of vision.
The paper describes the possibilities of new surgical technologies used to treat ovarian tumor and tumor-like masses in pregnant patients. The used surgical treatment contributes to the normal course of pregnancy and the maintenance of reproductive function. Laparoscopic intervention allows timely surgical treatment in a required volume and has no negative impact on the course of pregnancy and fetal and neonatal status.
Early response genes are a group of proto-oncogenes that are the first to be activated in cell stimulation with different growth factors and to be involved in the regulation of cell proliferation and differentiation. Large amount of information supporting that altered expression of these genes is one of the central and earliest events of carcinogenesis has been accumulated. In this connection, it is promising to use early response genes as diagnostic and prognostic markers for the detection and combination therapy of cancer of the cervix uteri, one of the most common gynecological malignancies characterized by high mortality rates and difficulties in early diagnosis. The theoretical basis for these promises is the found mechanisms for the interaction of early response genes with human papillomavirus genome, the main cause of cervix uteri cancer.
GYNECOLOGY. TREATMENT
The paper analyzes the strategy and tactics of beam and intracavitary radiation within the framework of chemoradiotherapy in 112 pa- tients with inoperable FIGO stages IIa–IIIb cancer of the cervix uteri. The parameters that are important to plan general radiotherapy stages are assessed; the bases for optimization decisions and the specific features of maintenance therapy, which ensure a 15–25 % increase in the efficiency of treatment with its satisfactory tolerability, are given.
The efficacy and safety of intravenous topotecan (hycamtin) given in a dose of 4 mg/m2 on days of 1, 8, 15 of a 28-day cycle of its therapy were evaluated in patients with recurrent ovarian cancer (OC).
Preliminary analysis of the safety and toxicity of the topotecan regimen demonstrated no impact on quality of life, easiness-to-use, and possible outpatient use. Topotecan showed to be effective as second- and higher line therapy for recurrent OC to carry out a platinum reduction.
GYNECOLOGY. PROBLEM
ISSN 1999-8627 (Online)